Literature DB >> 25902790

Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis.

Francesco Ciccia1, Giuliana Guggino1, Aroldo Rizzo2, Laura Saieva3, Sergio Peralta4, AnnaRita Giardina1, Alessandra Cannizzaro2, Guido Sireci3, Giacomo De Leo3, Riccardo Alessandro3, Giovanni Triolo1.   

Abstract

BACKGROUND: The aim of the study was to better characterise the immunological origin and the behaviour of interleukin (IL)-23-responsive innate lymphoid cells (ILCs) in the gut, synovial fluid (SF) and bone marrow (BM) of patients with ankylosing spondylitis (AS).
METHODS: ILC1, ILC2 and ILC3 cells were determined and characterised by confocal microscopy and flow cytometry in ileal and BM biopsies, in peripheral blood (PB) and SF mononuclear cells obtained from patients with AS and controls. Mucosal vascular addressin cell adhesion molecule 1 (MADCAM-1), IL-7, IL-15 and aggregates of lymphoid tissue inducer cells (LTi) were evaluated by immunohistochemistry. The in vitro ability of epithelial cells in driving the differentiation of ILC3 and the effect of tumour necrosis factor inhibitors (TNFi) on the frequency of ILC3 and the expression of MADCAM1 were also assessed.
RESULTS: ILC3 characterised as Lyn(-)RORc(-)Tbet(+) NKp44(+) cells were significantly expanded in the gut, SF and BM of patients with AS compared with controls, produced high levels of IL-17 and IL-22 and expressed α4β7. MADcAM1 was overexpressed in BM and ileal high endothelial venules. IL-7 was significantly increased in AS gut, especially in the context of Paneth cells, and accompanied by the presence of aggregates of c-kit/IL-7R(+) cells (LTi). In in vitro experiments, epithelial cells from patients with AS actively induced differentiation of ILC3 from LTi. TNFi efficacy was accompanied by a significant decrease in the percentage of intestinal and circulating ILC3 and in the expression of MADCAM1.
CONCLUSIONS: Gut-derived IL-17(+) and IL-22(+)ILC3 are expanded in the peripheral blood, SF and inflamed BM of patients with AS, suggesting the presence of an active homing axis between the gut and the inflamed sacroiliac joints. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Ankylosing Spondylitis; Cytokines; Inflammation

Mesh:

Substances:

Year:  2015        PMID: 25902790     DOI: 10.1136/annrheumdis-2014-206323

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  94 in total

1.  Vedolizumab-Induced De Novo Extraintestinal Manifestations.

Authors:  Liege I Diaz; Tara Keihanian; Ingrid Schwartz; Su Bin Kim; Fernando Calmet; Maria Alejandra Quintero; Maria T Abreu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-02

Review 2.  Innate lymphoid cells in autoimmunity: emerging regulators in rheumatic diseases.

Authors:  Medya M Shikhagaie; Kristine Germar; Suzanne M Bal; Xavier Romero Ros; Hergen Spits
Journal:  Nat Rev Rheumatol       Date:  2017-02-02       Impact factor: 20.543

Review 3.  Expression and Metabolomic Profiling in Axial Spondyloarthritis.

Authors:  Darren D O'Rielly; Guangju Zhai; Proton Rahman
Journal:  Curr Rheumatol Rep       Date:  2018-06-27       Impact factor: 4.592

Review 4.  The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis.

Authors:  Leticia Garcia-Montoya; Helena Marzo-Ortega
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-09-06       Impact factor: 5.346

Review 5.  The Bench-to-Bedside Story of IL-17 and the Therapeutic Efficacy of its Targeting in Spondyloarthritis.

Authors:  Judith A Smith
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

Review 6.  The balance of power: innate lymphoid cells in tissue inflammation and repair.

Authors:  Jim G Castellanos; Randy S Longman
Journal:  J Clin Invest       Date:  2019-06-10       Impact factor: 14.808

Review 7.  Pathogenesis of ankylosing spondylitis - recent advances and future directions.

Authors:  Vidya Ranganathan; Eric Gracey; Matthew A Brown; Robert D Inman; Nigil Haroon
Journal:  Nat Rev Rheumatol       Date:  2017-04-27       Impact factor: 20.543

Review 8.  Immune modules shared by innate lymphoid cells and T cells.

Authors:  Michelle L Robinette; Marco Colonna
Journal:  J Allergy Clin Immunol       Date:  2016-11       Impact factor: 10.793

Review 9.  Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.

Authors:  Jurij Hanzel; Christopher Ma; Niels Vande Casteele; Reena Khanna; Vipul Jairath; Brian G Feagan
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

10.  Correlation of serum MMP3 and other biomarkers with clinical outcomes in patients with ankylosing spondylitis: a pilot study.

Authors:  Dongyi He; Qi Zhu; Quan Zhou; Qing Qi; Hongmei Sun; Liza M Zachariah; Grace Wang; John D Reveille; Yongtao Guan; Xiaodong Zhou
Journal:  Clin Rheumatol       Date:  2017-04-22       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.